ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1581

Presence of Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study

Nalia Domínguez-Lirón1, Eugenio De Miguel2, Agustín Martínez-Sanchis3, Diana Peiteado2, Blanca Garcia-Magallon4, Esther Vicente-Rabaneda5, Enrique Calvo6, Basilio Rodríguez7, Alejandro Prada8, Boris Anthony Blanco Cáceres9, José Antonio Bernal10, Francisca Sivera11, Santos Castañeda5, Sonia Mínguez7, Laura Barrio8, Mónica Vázquez-Díaz9, José Miguel Senabre12, Cristina Bohorquez13 and Mariano Andrès3, 1Miguel Hernández University, Alicante, Spain, 2Hospital Universitario La Paz, Madrid, Spain, 3Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, 4Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 5Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 6Hospital Universitario Infanta Leonor, Madrid, Spain, 7Althaia Xarxa Assistencial Universitaria De Manresa, Manresa, Spain, 8Hospital Universitario de Torrejon, Madrid, Spain, 9Hospital Universitario Ramón y Cajal, Madrid, Spain, 10Hospital Marina Baixa (Villajoyosa), Alicante, Spain, 11Hospital Universitario de Elda, San Vicente del Raspeig, Spain, 12Hospital Marina Baixa, Villajoyosa, Spain, 13University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain

Meeting: ACR Convergence 2022

Keywords: gout, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: Metabolic and Crystal Arthropathies – Basic and Clinical Science

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: The applicability of the preliminary remission criteria for gout [PMID 26414176] in clinical practice is unknown. This study evaluates the sonographic prevalence of monosodium urate (MSU) deposition and associated inflammation in patients with gout in remission.

Methods: Observational cross-sectional multicenter study. Patients with gout (ACR/EULAR classification criteria +/- MSU crystal-proven) who met preliminary remission criteria were consecutively recruited at eleven Spanish rheumatology units. We determined the prevalence (with 95% confidence interval -CI) of sonographic signs of MSU crystal deposits (tophi, aggregates and double contour sign) and inflammation by power Doppler [PD] signal (graded as 0-3, positive if ≥1). We followed a sonographic assessment that scanned bilaterally 1st metatarsophalangeal and 2nd metacarpophalangeal joints, knees, talar cartilages and patellar and Achilles tendons. Associations between deposits and PD signal and clinical and laboratory variables were also analyzed.

Results: We report our initial 71 participants, mean aged 66 years (SD 9.8) and 93.0% males. Mean gout duration was 14.7 years (SD 12.2), the disease was tophaceous at baseline in 15.5%, and mean serum urate (SU) level in the preceding year was 4.7 mg/dl (SD 0.8). MSU deposits were detected in at least one scanned site in 88.7% of participants (95%CI 79.3-94.2%), with a median of 3 locations with deposits (range 0-9). Articular deposits (81.7%) were more common than tendinous deposits (45.1%), and aggregates were the most frequent sonographic finding (76.1%) [Figure 1]. A positive PD signal was present in 32.4% of participants (95%CI 22.7-44.0%), mainly at joints (29.6%). Prevalent deposits and positive PD signal were found associated both at joints (p=0.049) and tendons (p=0.015). Regarding secondary variables, sonographic deposits were associated with higher maximal SU levels registered at lab records (9.2 mg/dl, IQR 8.2-10.0 versus 7.9 mg/dL, IQR 7.8-8.7, p=0.030). Participants with positive PD signal showed higher SU urate levels in the preceding year (5.1 mg/dl, IQR 4.7-5.4, versus 4.8 mg/dl, IQR 4.1-5.2, p=0.057). No other associations were found.

Conclusion: Most patients with gout fulfilling remission criteria have sonographic MSU crystal deposits, and one third also show subclinical sonographic inflammation. These data suggest that achieving remission criteria should not be taken as the disease cure in gout management.

Supporting image 1


Disclosures: N. Domínguez-Lirón, None; E. De Miguel, None; A. Martínez-Sanchis, None; D. Peiteado, None; B. Garcia-Magallon, None; E. Vicente-Rabaneda, None; E. Calvo, None; B. Rodríguez, None; A. Prada, None; B. Blanco Cáceres, None; J. Bernal, None; F. Sivera, None; S. Castañeda, Roche; S. Mínguez, None; L. Barrio, None; M. Vázquez-Díaz, None; J. Senabre, None; C. Bohorquez, None; M. Andrès, Menarini, Grunenthal.

To cite this abstract in AMA style:

Domínguez-Lirón N, De Miguel E, Martínez-Sanchis A, Peiteado D, Garcia-Magallon B, Vicente-Rabaneda E, Calvo E, Rodríguez B, Prada A, Blanco Cáceres B, Bernal J, Sivera F, Castañeda S, Mínguez S, Barrio L, Vázquez-Díaz M, Senabre J, Bohorquez C, Andrès M. Presence of Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/presence-of-sonographic-crystal-deposits-and-power-doppler-signal-in-patients-with-gout-fulfilling-remission-criteria-a-multicenter-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/presence-of-sonographic-crystal-deposits-and-power-doppler-signal-in-patients-with-gout-fulfilling-remission-criteria-a-multicenter-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology